|
|
Jerini AG - Comparative Business Analysis Snapshot
Business Description
Jerini AG. The Group's principal activity is discovery and development of novel peptide based drugs. The Group focus on the capitalization of the potential of peptidomimetic and small molecule substrates transformed by Group's novel drug discovery method to therapeutic drugs. The Group operates through two business segments Jerini Pharma and Peptide Technologies. The Jerini Pharma segment is engaged in the discovery and development of targeted therapeutics for hereditary angioedema, liver cirrhosis, cancer and inflammatory diseases. The Peptide Technologies segment serves the life science industry and research community by producing custom and catalogue peptides using its integrated array-based technology platforms.
Competitor Analysis
This analysis compares Jerini AG with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
